Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab

Rajkumar Venkatramani, Marcio Malogolowkin, Leo Mascarenhas

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

As most active chemotherapy agents against Wilms tumor are incorporated into upfront therapy, particularly for those patients with high risk for recurrence, novel regimens are needed to treat children with relapsed Wilms tumor. We describe four consecutive patients with multiply relapsed Wilms tumor who were treated with a combination of vincristine, irinotecan, temozolomide, and bevacizumab. Two had a complete response, and two had a partial response to treatment. Hematological toxicity and diarrhea were the main side effects. This regimen has activity in patients with multiply relapsed Wilms tumor without excessive toxicity, and should be evaluated further in this setting. Pediatr Blood Cancer 2014;61:756-759.

Original languageEnglish (US)
Pages (from-to)756-759
Number of pages4
JournalPediatric Blood and Cancer
Volume61
Issue number4
DOIs
StatePublished - Apr 1 2014
Externally publishedYes

Keywords

  • Bevacizumab
  • Chemotherapy
  • Irinotecan
  • Relapse
  • Temozolomide
  • Vincristine
  • Wilms tumor

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Fingerprint Dive into the research topics of 'Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab'. Together they form a unique fingerprint.

  • Cite this